The US measles case count grew by 43 cases this past week, reaching 1,714, the Centers for Disease Control and Prevention (CDC) said today in its weekly update. The increase is much smaller than the 96-case jump last week, and more than half of the new cases are in Utah.

The CDC said all but 10 of the 2026 cases are from 32 states and New York City, with the rest travel-related. The number of affected states grew this week by one. Of all confirmed cases, 94% are associated with one of 17 outbreaks, compared with 48 outbreaks for all of last year, when the nation saw 2,286 measles cases, including three deaths. 

No measles-related deaths have been confirmed yet this year, but 96 patients have been hospitalized, or 6%, compared with 11% last year. Among all patients this year, 92% are unvaccinated or have an unknown vaccine status, similar to last year.

Of the 1,714 patients, 21% are children younger than five years, and 73% are kids and young adults up to age 19.

The United States is on pace to top last year’s measles total by summer. The country will likely lose its measles elimination status—which it gained in 2000—in November, when officials assess the data.

A substantial proportion of survivors of Nipah virus infection experience long-term neurologic deficits and fatigue, according to a study published yesterday in eClinicalMedicine.

The systematic review and meta-analysis, conducted by a team of British and Chinese researchers, analyzed evidence on post-acute sequelae after Nipah virus infection from eight studies published through November 2025.

Transmitted primarily by consumption of raw date palm sap that’s been contaminated by infected fruit bats, Nipah virus’ most prominent symptoms are acute encephalitis and respiratory disease. But instances of residual neurologic symptoms have been reported by survivors ever since the first outbreak of Nipah in Malaysia and Singapore in 1998 and1999.

“Synthesising information on pathogen epidemiology is critical for epidemic preparedness, and a better definition of disease burden has been identified as a strategic goal among key research priorities for the development of Nipah virus medical countermeasures,” the study authors wrote.

Of the eight studies included, three consisted of hospitalized Nipah encephalitis survivors, and five included survivors of Nipah virus infection more broadly. All but one focused on survivors of the Malaysia/Singapore outbreak. 

Meta-analysis of five of the studies estimated the pooled prevalence of total residual neurologic effects at 45% among Nipah encephalitis survivors and 24% among survivors of Nipah virus infection. An estimated 10% of Nipah virus infection survivors experienced late-onset or relapsing neurologic symptoms after initial recovery.

The studies reported 34 different potential post-acute neurologic symptoms. In the only controlled study, total residual neurological deficits, fatigue, and excessive daytime sleepiness were significantly more prevalent in Nipah infection survivors than in household controls. 

The study authors caution that the data are limited and more evidence is needed from recent Nipah virus outbreaks in India and Bangladesh, which have been caused by a different strain of the virus, to get a better sense of the prevalence of long-term neurologic symptoms among survivors. 

“Estimates from this study may not be generalisable to this different clinical setting and viral strain,” they wrote.